rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

Hemispherx May Provide Defense against H5N1

37 Posts
Pagina: 1 2 »» | Laatste | Omlaag ↓
  1. [verwijderd] 16 februari 2006 14:45

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    lijk mij een zeer belangrijk bericht:

    3 New Studies Show Hemispherx Biopharma's Ampligen(R) and Alferon(R) LDO May Provide Defense against Avian Flu
    Thursday February 16, 8:30 am ET

    PHILADELPHIA--(BUSINESS WIRE)--Feb. 16, 2006--Hemispherx Biopharma, Inc. (AMEX: HEB - News):

    * Tests Indicate Potential of Ampligen® As Vaccine Adjuvant, Boosts Existing Drugs Tamiflu®, Relenza® Up To 100 Times; Alferon® LDO Found to Stimulate Production of Interferon, Offering Natural Defense Against Virus
    * Consortium of Researchers to Present Findings at Today's ASM Biodefense Research Meeting in Washington, D.C.

    Hemispherx Biopharma, Inc. (AMEX: HEB - News), a leader in the clinical development and production of new drug entities for the treatment of viral and immune-based chronic disorders, today unveiled the results of laboratory testing that shows its two investigational immunotherapeutics, Ampligen® and Alferon®, are potentially useful against the H5N1, or avian flu, virus. The pre-clinical research indicates that Ampligen®, a specifically configured double-stranded RNA, can provide cross-protection against avian flu viral mutations as well as boost the effectiveness of Tamiflu and Relenza, the only two drugs formally recognized for combating bird flu, up to 100 times. Other lab tests, in healthy human volunteers, indicate that Alferon® LDO (Low-Dose Oral), a new delivery form of an anti-viral with prior regulatory approval for a category of sexually transmitted diseases, can stimulate genes that induce the production of interferon and other immune compounds, key building blocks in the body's defense system. Hemispherx Biopharma and collaborating government scientists are presenting detailed findings at today's American Society for Microbiology Biodefense Research Meeting in Washington, DC.

    The results of an animal study conducted by Dr. Hideki Hasegawa, M.D., Ph.D., Chief, Laboratory of Infectious Disease Pathology at the National Institute of Infectious Diseases in Tokyo, reveal that Ampligen® boosts IgA antibody levels by up to 500% when co-administered with vaccine--the exact antibodies that protect mucosal membranes of the nose and mouth, the specific entry points of an invading avian flu virus. In the course of the research, animals that were internasally administered with the vaccine Ampligen® registered an increase in antibodies that could fight the deadly virus. Some 80% of the Ampligen®-treated mice survived the virus's onslaught, while none survived in a corresponding placebo group.

    "As indicated in earlier peer-review reports, double-stranded RNA proved to be the most effective adjuvant for our nasal vaccine, and our new research reveals that Ampligen® is the only non-toxic dsRNA that's applicable to humans," said Dr. Hasegawa. "In addition, the alternative method of delivery used in this study--nasal mist--also has potential value. The tests suggest that not only does Ampligen® have the potential to be an effective therapy against the virus by itself, but also that the nasal mist method is far more economical, requiring only 1/20th of the injection dosage. This means we can substantially expand the supply and availability of this drug, and treat more people quickly and effectively."

    Independent lab research conducted at Utah State University under U.S. National Institutes of Health (NIH) sponsorship indicates that Ampligen® increases the efficacy of the two viral uptake inhibitors, Tamiflu and Relenza. The lab studies suggest that 50 to 100 times less Tamiflu may be used in conjunction with the experimental immunotherapeutic Ampligen® to achieve full inhibition with no multiplication of the virus, and no host cell damage. This may be a critical factor not only because of the potential shortage of Tamiflu, but also because 18% of all children are resistant to Tamiflu at conventional doses (as reported in the New England Journal of Medicine, December 2005). The effect was found be even stronger with Relenza (up to 500-fold potentiation) in the lab experiments.

    The experimental immunotherapeutic Alferon® N Injection is derived from an FDA-approved treatment for the Human papillomavirus (HPV, or genital warts). Hemispherx Biopharma has developed an oral delivery format for the product that requires much lower doses, called Alferon® LDO; new tests conducted in collaboration with the Cleveland Clinic suggest it may stimulate a large bank of anti-viral immune genes that may control the body's production of interferon and thereby potentially fight a wide range of diseases, including avian flu.

    "This is the race we have to win--to sufficiently mobilize the interferon system early enough so that it will knock out the virus multiplication," said Professor Luc Montagnier, President of the Foundation for AIDS Research and Prevention, who is widely credited with discovering the AIDS virus, HIV. "I believe that in addition to the anti-viral effect, Alferon® LDO will mobilize another important component of innate immunity, cells able to eliminate infected cells. It will act both on the native avian virus and on its humanized form."

    Results from Phase 1/Phase 2 clinical trials in healthy volunteers, being conducted at the Princess Margaret Hospital in Hong Kong indicate that Alferon® LDO may strengthen human immune responses via interferon-activated genes, potentially staving off infection should an individual be thereafter exposed to the virus. By priming the body's own interferon pump, Alferon® LDO might enable an infected host to produce enough interferon to overcome the virus. The studies being reported today include specific markers of immune response following exposure to Alferon® LDO in the absence of any viral exposure.

    "Given the potential for a pandemic, these results may have significant implications for control of the avian flu virus," said William A. Carter, M.D., Chairman and CEO of Hemispherx Biopharma. "In relevant animal models and human volunteer studies, both experimental immunotherapeutics, Ampligen® and Alferon® LDO may trigger the production of novel defense products as part of the body's immune system. Therefore, we are encouraged that these experimental immunotherapeutics represent a significant new path forward in potential preparation against the global spread."

    Hemispherx Biopharma intends to file a new drug application (NDA) for Ampligen® as a treatment for Chronic Fatigue Syndrome later this year. Since Alferon® N Injection is already FDA-approved, Hemispherx Biopharma would file various amendments globally to its existing approval licenses, reflecting a different method of delivery and different efficacy data on any potentially new therapeutic applications, including avian flu.
  2. [verwijderd] 16 februari 2006 15:11

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    8:32AM Hemispherx Biopharma says 3 new studies show HEB's Ampligen and Alferon L.D.O. may provide defense against Avian Flu (HEB) 2.66 : Co announced the results of laboratory testing that shows its two investigational immunotherapeutics, Ampligen and Alferon, are potentially useful against the H5N1, or avian flu, virus. The pre-clinical research indicates that Ampligen, a specifically configured double-stranded RNA, can provide cross-protection against avian flu viral mutations as well as boost the effectiveness of Tamiflu and Relenza, the only two drugs formally recognized for combating bird flu, up to 100 times. Other lab tests, in healthy human volunteers, indicate that Alferon L.D.O. (Low-Dose Oral), a new delivery form of an anti-viral with prior regulatory approval for a category of sexually transmitted diseases, can stimulate genes that induce the production of interferon and other immune compounds, key building blocks in the body's defense system. Hemispherx Biopharma and collaborating government scientists are presenting detailed findings at today's American Society for Microbiology Biodefense Research Meeting in Washington, DC.

    aandeel spuit prehours
  3. [verwijderd] 16 februari 2006 15:13

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Wie durft het aan om hier een bestens order neer te leggen? Het aandeel stijgt al een paar dagen achtereen met meer dan gemiddelde omzetten. Volgens mij wordt dit wel een kleine klapper.
  4. [verwijderd] 16 februari 2006 15:16

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    ik zei het al eerder in het heb topic, maar niemand die erop reageerde.

    ik hou ze vast..

    denk dat binnenkort deals gesloten kunnen worden icm met tamiflu etc..

    de tests zijn zeer overtuigend te noemen.
  10. [verwijderd] 16 februari 2006 16:28

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    aandeel wordt gedrukt, noteert rond de 2.93

    dit aandeel kan binnen nu en een paar weken maanden zo naar de 4 a 5 dollar.

    zeer veelbelovend, en als straks vogelgriep uitbreekt in amerika, gaat men automatisch bij heb aankloppen..

    zie 'm nog wel boven de 3 gaan vandaag
  12. bali bob 16 februari 2006 16:39

    • bali bob

      Lid sinds: 05 mei 2004

      Laatste bezoek: 17 feb 2024

    • Aanbevelingen

      Ontvangen: 1

      Gegeven: 10

    •    Aantal posts: 88

    gelet op de fantastische persberichten is er erg weinig handel in het aandeel! Of luistert iedereen ademloos naar heer Bernanke?

    klein plukje gekocht,ik verwacht toch wel iets beweging
  14. [verwijderd] 16 februari 2006 17:05

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    grote partijen houden 'm helaas tegen op 3

    ik denk als men een beetje logisch nadenkt, had het aandeel allang op 4 gestaan minimaal...

    maar goed wat niet is kan nog komen.
  15. [verwijderd] 16 februari 2006 17:10

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ook een klein beetje gekocht. Ben benieuwd waar dit naar toe gaat. Wordt wel heel erg onder de $3 gehouden op dit moment. Dit kan gaan dalen of juist hard gaan stijgen na de lunch pauze.
  16. [verwijderd] 17 februari 2006 12:59

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    yep alles wordt gedaan om de koers onder de 3 te houden, althans gister wel.

    erg jammer.

    Wie weet komt heb binnenkort met meer nieuws, eventueel contracten en milestone payments.. Het is nieuws zoals gister gepresenteerd is in ieder geval groots.

    Mocht ie dalen koop ik nog flink bij. Ik denk dat dit aandeel wel eens hard kan gaan stijgen als de grote partijen het toelaten
  19. [verwijderd] 17 februari 2006 16:38

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Hemispherx BioPharma Inc

    HEB3.14, +0.20, +6.8% ) was up substantially for the second day, jumping 8% to $3.18. The biotech group unveiled promising data on Thursday that indicated its drug Ampligen could greatly boost the strength of avian flu vaccines and the avian flu-fighting drugs Tamiflu and Relenza. See full story. End of Story
37 Posts
Pagina: 1 2 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.131
AB InBev 2 5.541
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.270
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.903
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.867
Aedifica 3 927
Aegon 3.258 323.113
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.907
Agfa-Gevaert 14 2.066
Ahold 3.538 74.353
Air France - KLM 1.025 35.301
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.054
Alfen 16 25.347
Allfunds Group 4 1.520
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.089
AMG 972 134.529
AMS 3 73
Amsterdam Commodities 305 6.747
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 497
Antonov 22.632 153.605
Aperam 92 15.072
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.807
Arcelor Mittal 2.035 321.018
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.360
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.647
ASML 1.766 110.777
ASR Nederland 21 4.515
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.184
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449